All Episodes

February 13, 2024 20 mins

Discover the lifesaving potential of monoclonal antibodies in the fight against canine parvovirus as Laurie Larson shares insights on this innovative treatment. We unravel the complexities of parvovirus and how traditional vaccines sometimes fall short due to maternal antibodies. Laurie takes us through the riveting findings of a pivotal study published in JAVMA, revealing the success of monoclonal antibodies in significantly boosting survival rates in dogs. This episode is a beacon of hope, shedding light on the urgent need for prompt intervention at the first sign of infection. For veterinarians seeking to navigate client communication about this groundbreaking treatment, our conversation offers indispensable advice. Together, we're rewriting the narrative on combating canine parvovirus.

Full article: https://doi.org/10.2460/javma.23.09.0541

INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ?

JAVMA ® : https://avma.org/JAVMAAuthors

AJVR ® : https://avma.org/AJVRAuthors

FOLLOW US:

JAVMA ® :

Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook

Instagram: JAVMA (@avma_javma) • Instagram photos and videos

Twitter: JAVMA (@AVMAJAVMA) / Twitter

AJVR ® :

Facebook: American Journal of Veterinary Research - AJVR | Facebook

Instagram: AJVR (@ajvroa) • Instagram photos and videos

Twitter: AJVR (@AJVROA) / Twitter

JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

Mark as Played

Advertise With Us

Popular Podcasts

Dateline NBC
Death, Sex & Money

Death, Sex & Money

Anna Sale explores the big questions and hard choices that are often left out of polite conversation.

Stuff You Should Know

Stuff You Should Know

If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.

Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

© 2024 iHeartMedia, Inc.